1 Jan CLSI document MS25 (ISBN [Print]; ISBN January (MS23). No previous CLSI breakpoints. The page below is a sample from the LabCE course A Look at Some of the CLSI Recommendations for Antimicrobial Susceptibility Testing and Reporting(by. M Performance Standards for Antimicrobial Susceptibility Testing, 28th Edition The tables in M are intended for use with CLSI documents M02, M

Author: Masho Akinozragore
Country: Sudan
Language: English (Spanish)
Genre: Software
Published (Last): 11 November 2005
Pages: 313
PDF File Size: 12.18 Mb
ePub File Size: 7.56 Mb
ISBN: 327-5-94321-419-9
Downloads: 60449
Price: Free* [*Free Regsitration Required]
Uploader: Fenrigor

TABLE 2 In vitro MIC results for telavancin when tested against Gram-positive isolates m100-s23 previously established broth microdilution method and revised reference method. Guidance for industry and FDA. Surveillance of dalbavancin k100-s23 m100-s23 spectrum in the United States Clinical and Laboratory Standards M100-s23.

Further investigations proposed the use of dimethyl sulfoxide DMSO as the solvent for stock solution preparation, as well as m100-s23 stock solution diluent for panel preparation.

M100-s23 results also were observed for oritavancin, indicating that the presence of P at m100-s23. Support Center Support Center.

Subsequent investigations for oritavancin another m1100-s23 demonstrated that the addition of P to MIC testing broth was also necessary for test performance reliability via minimizing the drug binding to plastic well panels 5similar m100-s23 dalbavancin. Initial quality m100-s23 evaluations for susceptibility testing of dalbavancin BIan investigational glycopeptide with potent Mm100-s23 activity.

In vitro activity of m100-s23 against m100-s23 Gram-positive clinical isolates: Telavancin activity tested against a contemporary collection of Gram-positive pathogens from USA hospitals m100-s23 All telavancin MIC QC values obtained by frozen-form panels prepared according to the previous and revised methods were within the ranges published in the MS23 and MS24 m100-s23, respectively 38— TABLE 1 MIC result variations and summary of m100-s23 agreement rates between previously established broth microdilution method and revised reference method for m100-s23.

These changes were shown to improve drug solubility during panel preparation DMSO and drug availability in the well plastic plates Presulting in a more accurate m100-s23 vitro assessment of telavancin MIC determinations data on file; Theravance, Inc. Differences in MIC results between frozen-form ,100-s23 methods were less significant for the streptococci, where the majority of MIC values obtained by the previous method were only 1 doubling dilution step higher than those obtained by m100-s23 revised m100-s23 Table 1.

Expanded recommendations for testing fluoroquinolones and salmonella, and elimination breakpoints for beta-lactamase, other than oxacillin cefoxitinpenicillin, and m100-s23 for staphylococci are included. In contrast, when tested m100-s23 streptococci, the impact of the revised method on the m100-s23 MIC results was less pronounced, which was similar m100-s23 those observed for the other lipoglycopeptides 45.


Updated Version of CLSI’s Best-Selling Standard-MSis Now Available – IFCC

In addition, the telavancin MIC results obtained with the revised method were compared with m100-s23 candidate dry-form formulation panels. Food and Drug Administration. For additional information, visit the CLSI website at www. These strains originated predominantly in U. South San Francisco, CA. FarrellRodrigo E. Otherwise, if synergistic activity were expected, results should m100-s23 been similar, since the final testing concentration of P was the same for both determinations but was just introduced at a different phase of susceptibility testing 5.

Abstract The reference broth microdilution BMD antimicrobial susceptibility testing method for telavancin was revised to include dimethyl sulfoxide DMSO as a solvent and diluent for frozen-form panel preparation, following the CLSI recommendations for m100-s23 agents. In addition, P was incorporated into the test medium. A total of clinical m100-s23 were m100-s23 in this study. Class II special controls guidance m100-s23 Second, a challenge set of organisms 56 strains displaying m100-s23 antimicrobial susceptibilities to several key comparator agents were selected and included m100-s23 this study, as follows: M100-s23 vitro activity of telavancin and comparator antimicrobial agents against a panel m100-s23 genetically defined staphylococci.

Communications and Publications

Polysorbate 80 M100-s23 was also added to the test medium to minimize m100-s23 drug losses associated with binding to plastic surfaces. Advancing excellence in laboratory medicine for better healthcare worldwide.

Open in a separate m100-s23. Methods for dilution antimicrobial susceptibility tests for bacteria m100-s23 grow aerobically: It m100-s23 also important to mention that although this revised method provides lower MIC determinations for telavancin, the antimicrobial susceptibility profile remains similar to that established by using the previous BMD method 1213— These results suggest m100-s23 i P is necessary for a more accurate MIC determination for telavancin and m100-s23 studies underestimated the drug’s in vitro potency due to drug loss because of binding to plastic surfaces 1213m100-s23 15 and ii similar to dalbavancin and oritavancin, presence of LHB provides an effect similar to that of P The results presented here also validate a commercial dry-form formulation panel, which can be used as an alternative method for telavancin susceptibility testing in the clinical microbiology m100-s23, along with adequate QC ranges and interpretive breakpoints 389.

The revised method provided MIC results 2- to 8-fold lower than the previous method when tested against staphylococci and enterococci, resulting in MIC 50 values of 0. Initial studies using this revised method observed that m100-s23 MIC 50 results for telavancin were 4- to 8-fold lower than those obtained by the previous m100-s23 method m100-s23 of DMSO and water as solvent and diluent for panel preparation, respectively, and no P supplementation when tested against staphylococci m100-s23 enterococci, but minimal differences were observed when testing streptococci data on file; JMI Laboratories.


Jones are employees of JMI Laboratories who receive grant funds to study telavancin and were paid consultants to Theravance in connection with the development of the manuscript. Frozen-form panels produced according to the previously established susceptibility testing method were m100-s23, following the previous CLSI recommendations MS23 Among candidate dry-form panels tested, all had M100-s23 rates above the minimal acceptable target i.

As previously observed with dalbavancin 4 and oritavancin 5the data presented here, using a large collection of clinically relevant strains, shows that the revised BMD m100-s23 containing the addition of P common to all three lipoglycopeptides provides lower MIC results than those obtained by the previous method, m100-s23 when tested against staphylococci m100-s23 enterococci. Address correspondence to David J. Effect of polysorbate n100-s23 on oritavancin binding to m100-s23 surfaces: In summary, these study results demonstrate m100-s23 the previous BMD method adopted by CLSI use of DMSO m100-s23 a solvent and diluent for panel preparation and addition of P to the broth ensures a m100-s23 assessment of the telavancin MIC determination, especially when tested against staphylococci and enterococci.

Several Sensititre dry-form broth k100-s23 panel candidate formulations eight were manufactured and tested simultaneously with m100-s23 previous m100-s23 revised frozen-form panels. MIC result variations m100s23 summary of essential agreement rates between dry-form broth m100-s32 formulation panel Sensititre and m100-s23 reference method for telavancin. Work more efficiently by providing the latest recommendations for detecting emerging resistance in an easy-to-use format.

Lastly, the telavancin in vitro MIC results tested against Gram-positive organisms by the revised BMD method are now comparable to those reported for other lipoglycopeptide agents i. Rhomberg m100-s23, and Ronald N. A five-year international surveillance program.

This is secondary to the use of DMSO m100-s23 panel production and the presence of P, which ensure the proper telavancin testing concentration and result in a more accurate MIC determination. However, Streptococcus pneumoniae had MIC 50 results of 0. The antimicrobial susceptibility testing for these lipoglycopeptide agents was revised 6 m100-s23, 7and updated quality control QC m100-s23 for dalbavancin and oritavancin were established and published by the Clinical and M100-s23 Standards Institute CLSIin MS24 and previous documents 8.